Home › Companies › Allogene Therapeutics, Inc. › 2025-2026

Allogene Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Allogene Therapeutics, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

10Reported items
179Asset managers
1,492Fund votes
2026-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Allogene Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Allogene Therapeutics, Inc.

These tallies are Allogene Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Allogene Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Deborah Messemer	202,325,767	--	--	26,099,641	54,299,010	Majority: yes
Elect Director: Vicki Sato, Ph.D.	202,326,299	--	--	26,099,109	54,299,010	Majority: yes
Elect Director: Owen Witte, M.D.	189,310,484	--	--	39,114,924	54,299,010	Majority: yes
Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in	213,098,167	11,951,256	3,375,985	--	54,299,010	Majority: yes
Proposal 3. Approval, on an Advisory Basis, Say-On-Pay Vote Frequency The Company's stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive offi	221,767,995	6,535,254	122,159	--	54,299,010	Majority: yes
The Amendment was filed with the Secretary of State of the State of Delaware on June 18, 2026 and effective as of such date. A copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.	282,022,884	503,156	198,378	--	0	Majority: yes

Source: Allogene Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the Allogene Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 179 asset managers that disclosed a Allogene Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Allogene Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 213,098,167AGAINST: 11,951,256

Allogene Therapeutics, Inc.’s own tally for this item (“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 213,098,167 for, 11,951,256 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 172 asset managers below cast 97% of the shares they voted on this item FOR (186,506,499 for, 5,901,649 against).

FOR 95%

FOR: 186,506,499 (95.5%)AGAINST: 5,901,649 (3.0%)ABSTAIN: 2,955,370 (1.5%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	24,623,690	38	12	For
PFIZER INC	22,032,040	0	0	For
Fidelity	21,980,127	0	0	For
Frazier Life Sciences Management, L.P.	18,796,668	0	0	For
BlackRock	18,170,924	107,889	0	For
PRIMECAP MANAGEMENT CO/CA/	12,721,798	0	0	For
T. Rowe Price	8,824,750	0	0	For
Citadel	8,215,662	0	0	For
State Street	7,841,600	4,344	0	For
Aberdeen	3,898,614	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,818,375	0	0	For
Charles Schwab	3,743,526	0	0	For
PRIMECAP Odyssey Funds	3,375,270	0	0	For
Candriam S.C.A.	0	2,997,318	0	Against
Wildcat Capital Management, LLC	0	0	2,920,787	Abstain
DE Shaw	2,800,075	0	0	For
Nuveen	2,477,660	0	0	For
TIAA	2,421,840	0	0	For
AQR	2,169,457	0	0	For
DAFNA Capital Management LLC	2,000,000	0	0	For
Two Sigma	1,554,353	0	0	For
Woodline Partners LP	1,496,992	0	0	For
Northern Trust	894,011	0	0	For
Holocene Advisors, LP	843,864	0	0	For
BBR PARTNERS, LLC	798,899	0	0	For

Showing the 25 largest of 172 asset managers. See all 172 in the interactive database.

2. To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

10%ONE YEAR 52.9%1 YEAR 35%

The 170 asset managers below cast 100% of the shares they voted on this item FOR (18,969,547 for, 0 against).

FOR: 18,969,547 (9.7%)ABSTAIN: 3,006,870 (1.5%)ONE YEAR: 103,179,363 (52.9%)1 YEAR: 67,945,354 (34.8%)1-YEAR: 1,496,992 (0.8%)THREE YEARS: 443,266 (0.2%)3 YEARS: 57,741 (0.0%)SHARES YEAR 1: 3,000 (0.0%)1.0: 584 (0.0%)3.0: 3 (0.0%)2.0: 1 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	0	12	One Year
PFIZER INC	0	0	1 Year
Fidelity	0	0	One Year
Frazier Life Sciences Management, L.P.	18,796,668	0	For
BlackRock	0	0	1 Year
PRIMECAP MANAGEMENT CO/CA/	0	0	1 Year
T. Rowe Price	0	0	One Year
Citadel	0	0	One Year
State Street	0	0	One Year
Aberdeen	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	One Year
Charles Schwab	0	0	1 Year
PRIMECAP Odyssey Funds	0	0	1 Year
Candriam S.C.A.	0	0	One Year
Wildcat Capital Management, LLC	0	2,920,787	Abstain
DE Shaw	0	0	One Year
Nuveen	0	0	One Year
TIAA	0	0	One Year
AQR	0	0	One Year
DAFNA Capital Management LLC	0	0	1 Year
Two Sigma	0	0	One Year
Woodline Partners LP	0	0	1-Year
Northern Trust	0	0	1 Year
Holocene Advisors, LP	0	0	One Year
BBR PARTNERS, LLC	0	0	1 Year

Showing the 25 largest of 170 asset managers. See all 170 in the interactive database.

3. Election of Directors: Deborah Messemer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 202,325,767WITHHELD: 26,099,641

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Messemer”): 202,325,767 for, 26,099,641 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 50 asset managers below cast 100% of the shares they voted on this item FOR (62,586,527 for, 0 against).

FOR 97%

FOR: 62,586,527 (96.6%)ABSTAIN: 2,198,905 (3.4%)

Largest asset managers voting on “Election of Directors: Deborah Messemer” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	22,783,583	23,765	For
Fidelity	12,491,517	0	For
BlackRock	8,024,301	0	For
State Street	5,360,206	13,091	For
T. Rowe Price	3,707,029	0	For
PRIMECAP Odyssey Funds	3,375,270	0	For
TIAA	2,421,840	0	For
Charles Schwab	1,871,494	0	For
Invesco	591,457	0	For
Equitable	331,345	165,041	For
Nationwide	47,412	318,050	Abstain
JPMorgan	306,515	0	For
BRIDGEWAY FUNDS INC	0	250,000	Abstain
Columbia Threadneedle	244,527	0	For
QUANTITATIVE MASTER SERIES LLC	237,500	0	For
ETFis Series Trust I	0	172,026	Abstain
John Hancock	125,876	40,876	For
GuideStone	0	166,200	Abstain
Brighthouse	81,804	82,267	Abstain
ProShares	0	154,377	Abstain
Delaware/Macquarie	0	146,779	Abstain
AIG/SunAmerica	0	140,772	Abstain
Dimensional	0	113,711	Abstain
Direxion Shares ETF Trust	0	113,627	Abstain
Lincoln Financial	93,800	17,215	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. Election of Directors: Owen Witte, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%

FOR: 189,310,484WITHHELD: 39,114,924

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Owen Witte, M.D.”): 189,310,484 for, 39,114,924 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 50 asset managers below cast 100% of the shares they voted on this item FOR (53,952,168 for, 0 against).

FOR 83%ABSTAIN 17%

FOR: 53,952,168 (83.3%)ABSTAIN: 10,833,264 (16.7%)

Largest asset managers voting on “Election of Directors: Owen Witte, M.D.” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	22,771,852	35,495	For
Fidelity	9,446,272	3,045,245	For
BlackRock	8,024,301	0	For
State Street	3,863	5,369,434	Abstain
T. Rowe Price	3,707,029	0	For
PRIMECAP Odyssey Funds	3,375,270	0	For
TIAA	2,421,840	0	For
Charles Schwab	1,871,494	0	For
Invesco	591,457	0	For
Equitable	331,345	165,041	For
Nationwide	47,412	318,050	Abstain
JPMorgan	306,515	0	For
BRIDGEWAY FUNDS INC	0	250,000	Abstain
Columbia Threadneedle	244,527	0	For
QUANTITATIVE MASTER SERIES LLC	237,500	0	For
ETFis Series Trust I	0	172,026	Abstain
John Hancock	125,876	40,876	For
GuideStone	0	166,200	Abstain
Brighthouse	81,804	82,267	Abstain
ProShares	0	154,377	Abstain
Delaware/Macquarie	0	146,779	Abstain
AIG/SunAmerica	0	140,772	Abstain
Dimensional	0	113,711	Abstain
Direxion Shares ETF Trust	0	113,627	Abstain
Lincoln Financial	0	111,015	Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. Election of Directors: Vicki Sato, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 202,326,299WITHHELD: 26,099,109

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Vicki Sato, Ph.D.”): 202,326,299 for, 26,099,109 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 50 asset managers below cast 100% of the shares they voted on this item FOR (62,586,527 for, 0 against).

FOR 97%

FOR: 62,586,527 (96.6%)ABSTAIN: 2,198,905 (3.4%)

Largest asset managers voting on “Election of Directors: Vicki Sato, Ph.D.” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	22,783,583	23,765	For
Fidelity	12,491,517	0	For
BlackRock	8,024,301	0	For
State Street	5,360,206	13,091	For
T. Rowe Price	3,707,029	0	For
PRIMECAP Odyssey Funds	3,375,270	0	For
TIAA	2,421,840	0	For
Charles Schwab	1,871,494	0	For
Invesco	591,457	0	For
Equitable	331,345	165,041	For
Nationwide	47,412	318,050	Abstain
JPMorgan	306,515	0	For
BRIDGEWAY FUNDS INC	0	250,000	Abstain
Columbia Threadneedle	244,527	0	For
QUANTITATIVE MASTER SERIES LLC	237,500	0	For
ETFis Series Trust I	0	172,026	Abstain
John Hancock	125,876	40,876	For
GuideStone	0	166,200	Abstain
Brighthouse	81,804	82,267	Abstain
ProShares	0	154,377	Abstain
Delaware/Macquarie	0	146,779	Abstain
AIG/SunAmerica	0	140,772	Abstain
Dimensional	0	113,711	Abstain
Direxion Shares ETF Trust	0	113,627	Abstain
Lincoln Financial	93,800	17,215	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.

CAPITAL STRUCTURE

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (64,722,894 for, 62,538 against).

FOR: 64,722,894 (99.9%)AGAINST: 62,538 (0.1%)

Largest asset managers voting on “To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized sha” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	22,783,658	23,690	For
Fidelity	12,491,517	0	For
BlackRock	8,024,301	0	For
State Street	5,366,376	6,921	For
T. Rowe Price	3,707,029	0	For
PRIMECAP Odyssey Funds	3,375,270	0	For
TIAA	2,421,840	0	For
Charles Schwab	1,871,494	0	For
Invesco	591,457	0	For
Equitable	496,386	0	For
Nationwide	365,462	0	For
JPMorgan	306,515	0	For
BRIDGEWAY FUNDS INC	250,000	0	For
Columbia Threadneedle	244,527	0	For
QUANTITATIVE MASTER SERIES LLC	237,500	0	For
ETFis Series Trust I	172,026	0	For
John Hancock	166,752	0	For
GuideStone	166,200	0	For
Brighthouse	132,144	31,927	For
ProShares	154,377	0	For
Delaware/Macquarie	146,779	0	For
AIG/SunAmerica	140,772	0	For
Dimensional	113,711	0	For
Direxion Shares ETF Trust	113,627	0	For
Lincoln Financial	111,015	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

7. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (64,753,289 for, 216 against).

FOR: 64,753,289 (100.0%)AGAINST: 216 (0.0%)ABSTAIN: 31,927 (0.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independe” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	22,807,345	1	0	For
Fidelity	12,491,517	0	0	For
BlackRock	8,024,301	0	0	For
State Street	5,373,082	215	0	For
T. Rowe Price	3,707,029	0	0	For
PRIMECAP Odyssey Funds	3,375,270	0	0	For
TIAA	2,421,840	0	0	For
Charles Schwab	1,871,494	0	0	For
Invesco	591,457	0	0	For
Equitable	496,386	0	0	For
Nationwide	365,462	0	0	For
JPMorgan	306,515	0	0	For
BRIDGEWAY FUNDS INC	250,000	0	0	For
Columbia Threadneedle	244,527	0	0	For
QUANTITATIVE MASTER SERIES LLC	237,500	0	0	For
ETFis Series Trust I	172,026	0	0	For
John Hancock	166,752	0	0	For
GuideStone	166,200	0	0	For
Brighthouse	132,144	0	31,927	For
ProShares	154,377	0	0	For
Delaware/Macquarie	146,779	0	0	For
AIG/SunAmerica	140,772	0	0	For
Dimensional	113,711	0	0	For
Direxion Shares ETF Trust	113,627	0	0	For
Lincoln Financial	111,015	0	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTESCOMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 221,767,995AGAINST: 6,535,254

Allogene Therapeutics, Inc.’s own tally for this item (“Proposal 3. Approval, on an Advisory Basis, Say-On-Pay Vote Frequency The Company's stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's ”): 221,767,995 for, 6,535,254 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR 99%

ONE YEAR: 1,150,946 (98.8%)1-YEAR: 13,559 (1.2%)1 YEAR: 623 (0.1%)2 YEARS: 192 (0.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Ghisallo Capital Management LLC	0	0	0	0	One Year
HBK INVESTMENTS L P	0	0	0	0	One Year
ALGERT GLOBAL LLC	0	0	0	0	1-Year
Coyle Financial Counsel LLC	0	0	0	0	1 Year
PINNEY & SCOFIELD, INC.	0	0	0	0	2 Years
NWI MANAGEMENT LP	0	0	0	0	--

9. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (1,165,128 for, 0 against).

FOR: 1,165,128 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Ghisallo Capital Management LLC	911,894	For
HBK INVESTMENTS L P	239,052	For
ALGERT GLOBAL LLC	13,559	For
Coyle Financial Counsel LLC	623	For

10. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 192 against).

AGAINST: 192 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at Allogene Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
PINNEY & SCOFIELD, INC.	0	192	0	0	Against
NWI MANAGEMENT LP	0	0	0	0	--

Largest Allogene Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Allogene Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 244,816,413 shares outstanding at the time of that meeting.

Top Allogene Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	10.06%
2	PFIZER INC	9.00%
3	Fidelity	8.98%
4	Frazier Life Sciences Management, L.P.	7.68%
5	BlackRock	7.47%
6	PRIMECAP MANAGEMENT CO/CA/	5.20%
7	T. Rowe Price	3.60%
8	Citadel	3.36%
9	State Street	3.20%
10	Aberdeen	1.59%

Reported Allogene Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Allogene Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Pfizer Inc.	9.00%	13D
Frazier Life Sciences Public Fund, L.P.	7.94%	13G
BlackRock	7.80%	13F
TPG GP A, LLC	7.65%	DEF14A
Arie Belldegrun, M.D.	5.56%	13G
Citadel Multi-Strategy Equities Master Fund Ltd.	5.45%	DEF14A
David Chang, M.D., Ph.D.	5.02%	DEF14A
David D. Chang, M.D., Ph.D.	5.02%	13G
Vanguard Group	3.78%	13F
State Street	3.54%	13F

Percentages above are of 244,816,413 shares outstanding, as reported by Allogene Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Allogene Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Allogene Therapeutics, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 179 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,492 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Allogene Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-22.

Allogene Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).